Comparing two multiple sclerosis medicines in everyday practice
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of multiple sclerosis (MS).
- You have not used Kesimpta or Ocrevus in the past 12 months before starting one of these medicines.
- You have been prescribed either Kesimpta or Ocrevus for at least 6 months.
- You have health insurance coverage for at least 12 months before and 6 months after starting the treatment.
- If you have not used any other MS treatments before, this study also looks at people new to treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a biosimilar drug that acts like Ocrevus to treat multiple sclerosis. It aims to help manage disease activity and slow progression, and may be an option if you have relapsing or progressive MS.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at the safety of Kesimpta (a multiple sclerosis medication) during pregnancy. It compares outcomes for women who took Kesimpta or other MS drugs while pregnant to those who did not.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.